Targeted delivery of chemotherapy with ultrasound and microbubbles - SONCHIMIO

CHRU TOURS0 sites15 target enrollmentMarch 2, 2018

Overview

No summary available.

Registry

who.int

Start Date

March 2, 2018

End Date

TBD

Last Updated

8 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

CHRU TOURS

•\- patient with non resectable liver metastases from colorectal cancer; patient with minimum two liver metastases which satisfy all the following criteria: diameter between 10 and 35 mm; arterially enhancing liver metastases detected with contrast enhanced ultrasound (CEUS); measurable liver metastases with CT\-scan
•\- age \= 18 years;
•\- ECOG/OMS 0\-1;
•\- life expectancy of at least 12 weeks;
•\- adequate bone marrow, liver and kidney function;
•\- written informed consent obtained from subject;
•\- subjects covered by or having the rights to social security.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1\.2 Adults (18\-64 years) yes

•\- Previous systemic or local treatment of liver metastases;
•\- neo\-adjuvant or adjuvant chemotherapy/radiotherapy in the 6 months prior to entering the study;
•\- patient with resectable liver metastasis and no contraindication to hepatic resection;
•\- indication for local ablative therapy (radiofrequency ablation or other validated hepatic\-directed modality of treatment);
•\- known contraindication to the injection of Sonovue®, of Gadolinium, of iodated contrast agent;
•\- contraindication to MRI or perfusion CT scan;
•\- Patient under legal protection;
•\- Pregnant or lactating woman, or woman with ability to procreate and without contraception;
•\- Inclusion in another therapeutic assay